Reviewer's report

Title: Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: A single-institution experience

Version: 2 Date: 7 December 2014

Reviewer: Tomoyuki Kato

Reviewer's report:

It is a small, retrospective study about feasibility of axitinib as first-line therapy for advanced RCC patients. Throughout the paper, the accuracy of description is lacking.

Major Compulsory Revisions
1. Axitinib is a molecular target agent commonly used as a second-line therapy for advanced renal cell cancer patients. The authors should discuss the validity of the use of axitinib as first line therapy.

Minor Essential Revisions
2. It is not clear whether the patients were treated with axitinib dose titration or not. The dose of axitinib should be described in more details in the TREATMENT section.
3. Abbreviations should be described in the proper position.
4. In the description of line 121-123, it is unclear how many patients received 6 mg/day axitinib.
5. Please specify the duration for which the patients underwent the therapies as well the duration for which they were under observation.
6. It contains multiple mistakes and misprints including misspelling of medical terms (e.g. page 14, 190th line, “Lini” should be changed to “Rini”). Thus, the text should be proofread carefully.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

'I declare that I have no competing interests